— Know what they know.
Not Investment Advice
Also trades as: BINV.ST (STO) · $vol 0M · 0H22.L (LSE) · $vol 0M

BOVNF OTC

BioInvent International AB (publ)
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: +0.0% 3Y: -30.0% 5Y: -28.8%
$3.29
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Strong Sell · Power 37 · $216.4M mcap · 48M float · 0.0016% daily turnover · Short 100% of daily vol

Cash Flow Trends

Operating Cash Flow
-$247M +35.0% ▲
Capital Expenditures
$7M +27.8% ▲
5Y CAGR: +1.6%
Free Cash Flow
-$254M +34.9% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$6M -103.1% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$278M-$51M-$330M-$471M-$332M
Depreciation & Amort.$15M$15M$17M$19M$20M
Stock-Based Comp.$1M$2M$3M$5M$0
Change in Working Capital$17M-$7M-$10M$8M$50M
Other Non-Cash Items$869K$2M-$21M$58M$16M
Operating Cash Flow-$246M-$41M-$342M-$380M-$247M
— Investing Activities —
Capital Expenditures-$13M-$12M-$13M-$10M-$7M
Acquisitions (Net)$0$0$0$0$0
Investment Purchases-$454M-$616M$0$0$0
Investment Sales$0$0$73M$574M$187M
Other Investing-$454M-$616M$0$0$0
Investing Cash Flow-$468M-$629M$60M$564M$180M
— Financing Activities —
Net Debt Issuance$0$0$0-$8M$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing-$6M-$6M-$8M$0-$9M
Financing Cash Flow$895M$273M$23M-$8M-$9M
Net Change in Cash$181M-$396M-$255M$175M-$6M
Cash End of Period$911M$515M$260M$435M$355M
Free Cash Flow-$259M-$54M-$355M-$391M-$254M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms